Adage Capital Partners Gp, L.L.C. Novavax Inc Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$6.67 - $9.52 $2 Million - $2.86 Million	300,000 New	300,000 $2.23 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $1.35 Million - $2.18 Million	-10,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $1.78 Million - $2.71 Million	10,000 New	10,000 $2.07 Million
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $45.6 Million - $129 Million	-403,283 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $29.8 Million - $52.8 Million	378,283 Added 1513.13%	403,283 $45 Million
Q3 2020 Nov 16, 2020	SELL	$79.44 - $178.51 $13.9 Million - $31.2 Million	-174,600 Reduced 87.47%	25,000 $2.71 Million
Q2 2020 Aug 14, 2020	BUY	$13.86 - $83.61 $2.77 Million - $16.7 Million	199,600 New	199,600 $16.6 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.